Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis

NCT02866903 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Peritoneal Carcinosis

Interventions

DRUG: intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy
DRUG: intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy
DRUG: intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy

Sponsor

Hospices Civils de Lyon